Plasma Fractionation Market to Grow at a CAGR of 7.2% During 2023-2030; Increasing Demand For Plasma-Derived Medicinal Products Supported The Market Reach In Developed And Developing Countries: Fortune Business Insights™

The global plasma fractionation market size was USD 30.64 billion in 2022. The market is projected to grow from USD 32.75 billion in 2023 to USD 53.33 billion by 2030 at a CAGR of 7.2% during 2023-2030. Fortune Business Insights™ publishes this information in its report titled, " Plasma Fractionation Market Size, Share & COVID-19 Impact Analysis, By Product (Albumin, Immunoglobulin (Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)), Coagulation Factors (Factor IX, Factor VIII, Prothrombin Complex Concentrates, Fibrinogen Concentrates, andOthers), Protease Inhibitors and Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology, and Others), By End-user (Hospitals & Clinics, Clinical Research Laboratories, and Others), and Regional Forecast, 2023-2030."

Plasma fractionation is the process used to produce valuable products through fractionation. Ethanol precipitation and fractionation are crucial for segregating therapeutic protein components from blood content in the plasma fractionation equipment. The plasma products are used in treating diseases such as trauma, congenital metabolic deficiencies, and other life-threatening diseases.

Restrictions on Plasma Collection Operations Amid Pandemic Hampered Market Growth

The outbreak of the COVID-19 pandemic created a huge impact on several businesses owing to stringent restrictions and limitations on operations imposed by governments. Also, due to the rising number of COVID-19 cases, hospitals were entirely occupied by emergency cases, and plasma therapies for non-critical cases were not prioritized during the initial lockdown phase. Plasma collection operations were halted, impacting the plasma fractionation market growth during the pandemic.

Grifols S.A. Acquired its First Plasma Donation Centre

In January 2022, Grifols S.A. acquired Prometic Plasma Resources Inc (PPR), its first donation center. This strategic acquisition will allow the company to ensure the availability of plasma medicines in Canada. Also, the company can gain easy access to plasma which helps the organization's profitability and enhance its organizational productivity.

Rising Technological Advancements in Healthcare Sector to Propel Growth  

The market of plasma fractionation is projected to grow prominently in the coming years, owing to the launch of new technologies by leading market players, which is expected to bolster market growth. Also, increasing demand for plasma-derived medicinal products supported the market reach in developed and developing countries. Furthermore, the surging incidences of immunodeficiency disorders are anticipated to drive the market development and expansion during the forecast period.

However, rise of recombinant therapies as an alternative to the plasma derived medicines to hamper the market growth.

Strategic Acquisitions Allow Companies to Expand Their Medicinal Availability

The key players in plasma fractionation implement various strategies to enhance their business performance. The leading companies form strategic alliances, partnerships, mergers, and acquisitions to expand their business reach and strengthen their market position. Strategic acquisitions allow companies to expand their business reach and enhance the availability of medicines.  The leading companies include Grifols, S.A., Biotest AG, CSL, Takeda Pharmaceutical Company Limited, and Octapharma.

Notable Industry Development:

• March 2023: Grifols, S.A. established a manufacturing facility with increased manufacturing capacity for human plasma therapies in Marburg, Germany.

List of Key Players Covered in the Report:

• CSL (U.S.)


• Grifols, S.A (Spain)


• Takeda Pharmaceutical Company Limited (Japan)


• Kedrion S.p.A (Italy)


• Octapharma (Switzerland)


• Bio Products Laboratory Ltd. (U.K.)


• Biotest AG (Germany)


• LFB (France)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614

Further Report Findings:

• Due to emerging technological advancements, North America is expected to dominate the global plasma fractionation market share. Furthermore, the presence of leading companies in the region is projected to bolster regional market growth. The regional market registered USD 17.16 billion in 2022.


• Europe led the market growth with the second position. The growth is owing to the growing occurrence of immunodeficiency and bleeding disorders in the region and increasing investments in these systems are propelling the market growth.

Table of Segmentation: